| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.33B | 9.92 | 70.86 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 720.1M | 4.25 | 11.18 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 881.27M | 2.22 | -1.73 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 572.64M | 7.30 | -2.38 | -117.82% | 0.18 | |||
| NKTRNektar Therapeutics | 719.28M | 35.36 | -4.07 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IMNMImmunome, Inc. | 2.52B | 22.85 | -4.57 | -35.5% | -23.01% | -84.4% | 0.03 | |
| IBRXImmunityBio, Inc. | 3.89B | 3.95 | -6.37 | 22.71% | -422.28% | |||
| NRIXNurix Therapeutics, Inc. | 1.91B | 18.86 | -6.55 | -29.15% | -292.5% | -65.76% | 0.05 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 23.59M | 49.13M | 61.8M | 75M | 68.83M | 117M | 285.14M | 627.24M |
| Revenue Growth % | - | 1.08% | 0.26% | 0.21% | -0.08% | 0.7% | 1.44% | 1.2% |
| Cost of Goods Sold | -96K | 0 | 0 | 0 | 0 | 65.36M | 144.21M | 234.58M |
| COGS % of Revenue | -0% | - | - | - | - | 0.56% | 0.51% | 0.37% |
| Gross Profit | 23.69M | 49.13M | 61.8M | 75M | 68.83M | 51.64M | 140.93M | 392.66M |
| Gross Margin % | 1% | 1% | 1% | 1% | 1% | 0.44% | 0.49% | 0.63% |
| Gross Profit Growth % | - | 1.07% | 0.26% | 0.21% | -0.08% | -0.25% | 1.73% | 1.79% |
| Operating Expenses | 9.6M | 64.2M | 194.31M | 75M | 461.11M | 507.26M | 580.41M | 695.9M |
| OpEx % of Revenue | 0.41% | 1.31% | 3.14% | 1% | 6.7% | 4.34% | 2.04% | 1.11% |
| Selling, General & Admin | 1.4M | 3.93M | 32.37M | 72.7M | 149.5M | 174.05M | 200.93M | 284.26M |
| SG&A % of Revenue | 0.06% | 0.08% | 0.52% | 0.97% | 2.17% | 1.49% | 0.7% | 0.45% |
| Research & Development | 8.2M | 60.64M | 161.94M | 232.16M | 313.35M | 335.65M | 382.22M | 413.54M |
| R&D % of Revenue | 0.35% | 1.23% | 2.62% | 3.1% | 4.55% | 2.87% | 1.34% | 0.66% |
| Other Operating Expenses | 0 | -2K | 0 | -229.87M | -1.74M | -2.43M | -2.73M | -1.91M |
| Operating Income | 13.78M | -1.53M | -132.51M | 0 | -392.29M | -455.62M | -439.49M | -303.24M |
| Operating Margin % | 0.58% | -0.03% | -2.14% | - | -5.7% | -3.89% | -1.54% | -0.48% |
| Operating Income Growth % | - | -1.11% | -85.38% | 1% | - | -0.16% | 0.04% | 0.31% |
| EBITDA | 14M | 149K | -129.35M | -298.16M | -378.37M | -437.23M | -419.03M | -279.88M |
| EBITDA Margin % | 0.59% | 0% | -2.09% | -3.98% | -5.5% | -3.74% | -1.47% | -0.45% |
| EBITDA Growth % | - | -0.99% | -869.13% | -1.31% | -0.27% | -0.16% | 0.04% | 0.33% |
| D&A (Non-Cash Add-back) | 217K | 1.68M | 3.16M | 9.93M | 13.92M | 18.39M | 20.45M | 23.36M |
| EBIT | 13.84M | -1.53M | -132.51M | -308.09M | -406.3M | -434.93M | -498.32M | -136.52M |
| Net Interest Income | 0 | 6.13M | 4.36M | -1.28M | 71K | -2.61M | 32.69M | 39.59M |
| Interest Income | 1K | 6.21M | 4.58M | 2.93M | 971K | 8.18M | 54.49M | 61.2M |
| Interest Expense | 0 | 82K | 223K | 4.21M | 900K | 10.8M | 21.79M | 21.61M |
| Other Income/Expense | -40K | 13.46M | 5.2M | -308.29M | -14.91M | 9.9M | -80.63M | 145.11M |
| Pretax Income | 13.84M | -1.62M | -127.32M | -308.29M | -407.2M | -445.72M | -520.12M | -158.13M |
| Pretax Margin % | 0.59% | -0.03% | -2.06% | -4.11% | -5.92% | -3.81% | -1.82% | -0.25% |
| Income Tax | 4.47M | 1.17M | -25.73M | -41.91M | -3.61M | 625K | -1.86M | 18.89M |
| Effective Tax Rate % | 0.68% | 1.72% | 0.8% | 0.86% | 0.99% | 1% | 1% | 1.12% |
| Net Income | 9.37M | -2.78M | -101.59M | -266.37M | -403.58M | -446.35M | -518.25M | -177.03M |
| Net Margin % | 0.4% | -0.06% | -1.64% | -3.55% | -5.86% | -3.81% | -1.82% | -0.28% |
| Net Income Growth % | - | -1.3% | -35.49% | -1.62% | -0.52% | -0.11% | -0.16% | 0.66% |
| Net Income (Continuing) | 9.37M | -2.78M | -101.59M | -266.37M | -403.58M | -446.35M | -518.25M | -177.03M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.14 | -0.06 | -2.02 | -5.14 | -5.48 | -5.62 | -5.88 | -1.94 |
| EPS Growth % | - | -1.4% | -35.33% | -1.54% | -0.07% | -0.03% | -0.05% | 0.67% |
| EPS (Basic) | 0.14 | -0.06 | -2.02 | -5.14 | -5.48 | -5.62 | -5.88 | -1.94 |
| Diluted Shares Outstanding | 66M | 50.11M | 66M | 59.08M | 70.43M | 79.52M | 88.04M | 91.43M |
| Basic Shares Outstanding | 66M | 50M | 66M | 59.08M | 70.43M | 79.52M | 88.04M | 91.43M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 230.9M | 326.96M | 207.1M | 593.94M | 949.85M | 1.1B | 1.5B | 1.28B |
| Cash & Short-Term Investments | 2.12M | 216.18M | 159.18M | 506.07M | 882.39M | 1.03B | 1.31B | 1.12B |
| Cash Only | 2.12M | 210.17M | 83.62M | 456.07M | 688.94M | 786.03M | 1.28B | 286.75M |
| Short-Term Investments | 0 | 6.01M | 75.56M | 50M | 193.46M | 239.62M | 31M | 835.93M |
| Accounts Receivable | 228.74M | 108.57M | 35.76M | 82.62M | 58.55M | 44.52M | 157.06M | 124.89M |
| Days Sales Outstanding | 3.54K | 806.53 | 211.19 | 402.06 | 310.49 | 138.87 | 201.05 | 72.67 |
| Inventory | 11K | 1.14M | 1.16M | 1.8M | 1.75M | 10.35M | 19.43M | 23.9M |
| Days Inventory Outstanding | -41.82 | - | - | - | - | 57.82 | 49.18 | 37.19 |
| Other Current Assets | 760K | 255K | 0 | 0 | 1.44M | 1.27M | 357K | 70K |
| Total Non-Current Assets | 7.79M | 102.09M | 80.61M | 128.15M | 169.62M | 231.84M | 350.81M | 386.24M |
| Property, Plant & Equipment | 2.93M | 33.13M | 80.09M | 112.11M | 142.96M | 161.67M | 189.68M | 201.59M |
| Fixed Asset Turnover | 8.06x | 1.48x | 0.77x | 0.67x | 0.48x | 0.72x | 1.50x | 3.11x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 2K | 49K | 519K | 2.85M | 16.8M | 68.69M | 4.06M | 174.22M |
| Long-Term Investments | -4.86M | -1.24M | 0 | 0 | 4.71M | 0 | 4.36M | 4.36M |
| Other Non-Current Assets | 4.86M | 1.24M | 0 | 13.19M | 5.15M | 1.49M | 152.42M | 6.06M |
| Total Assets | 238.69M | 429.05M | 287.71M | 722.09M | 1.12B | 1.33B | 1.85B | 1.67B |
| Asset Turnover | 0.10x | 0.11x | 0.21x | 0.10x | 0.06x | 0.09x | 0.15x | 0.38x |
| Asset Growth % | - | 0.8% | -0.33% | 1.51% | 0.55% | 0.19% | 0.39% | -0.1% |
| Total Current Liabilities | 52.12M | 159.19M | 127.76M | 115.57M | 229.2M | 297.79M | 216.42M | 277.64M |
| Accounts Payable | 4.33M | 7.32M | 9.59M | 4.91M | 7.04M | 31.69M | 20.16M | 37.19M |
| Days Payables Outstanding | -16.48K | - | - | - | - | 176.98 | 51.02 | 57.87 |
| Short-Term Debt | 0 | 0 | 1.03M | 1.79M | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 304K | 451K | 1000K | 1000K |
| Other Current Liabilities | 38.08M | 34.16M | 64.22M | 31.45M | 87.9M | 67M | 68K | 0 |
| Current Ratio | 4.43x | 2.05x | 1.62x | 5.14x | 4.14x | 3.69x | 6.92x | 4.62x |
| Quick Ratio | 4.43x | 2.05x | 1.61x | 5.12x | 4.14x | 3.66x | 6.83x | 4.54x |
| Cash Conversion Cycle | 19.98K | - | - | - | - | 19.7 | 199.21 | 51.99 |
| Total Non-Current Liabilities | 174.4M | 261.21M | 282.82M | 6.7M | 124.32M | 288.86M | 380.82M | 351.96M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 120.46M | 260.93M | 281.33M | 301.2M |
| Capital Lease Obligations | 205K | 3.94M | 5.08M | 1.91M | 1.59M | 20.04M | 44.17M | 44.61M |
| Deferred Tax Liabilities | -174.2M | -213.2M | 0 | 4.24M | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | -274.52M | 396K | 233K | 56K | 0 |
| Total Liabilities | 226.53M | 420.4M | 410.58M | 122.27M | 353.52M | 586.65M | 597.24M | 629.61M |
| Total Debt | 269K | 4.32M | 6.11M | 3.7M | 122.97M | 284.53M | 328.67M | 350.6M |
| Net Debt | -1.85M | -205.85M | -77.51M | -452.37M | -565.97M | -501.5M | -949.04M | 63.85M |
| Debt / Equity | 0.02x | 0.50x | - | 0.01x | 0.16x | 0.38x | 0.26x | 0.34x |
| Debt / EBITDA | 0.02x | 28.97x | - | - | - | - | - | - |
| Net Debt / EBITDA | -0.13x | -1381.54x | - | - | - | - | - | - |
| Interest Coverage | - | -18.71x | -594.23x | - | -435.87x | -42.20x | -20.17x | -14.03x |
| Total Equity | 12.17M | 8.65M | -122.87M | 597.77M | 765.94M | 744.31M | 1.25B | 1.04B |
| Equity Growth % | - | -0.29% | -15.21% | 5.87% | 0.28% | -0.03% | 0.68% | -0.17% |
| Book Value per Share | 0.18 | 0.17 | -1.86 | 10.12 | 10.88 | 9.36 | 14.21 | 11.38 |
| Total Shareholders' Equity | 12.17M | 8.65M | -122.87M | 597.77M | 765.94M | 744.31M | 1.25B | 1.04B |
| Common Stock | 20K | 20K | 20K | 27K | 31K | 33K | 36K | 37K |
| Retained Earnings | 8.47M | 5.69M | -127.28M | -116.53M | -520.11M | -966.46M | -1.48B | -1.66B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -236K | 8.63M | 485K | 5.96M | 4.86M | 14.67M | 98.92M | -68.16M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -2.38M | 307.68M | -83.06M | -223M | -198.47M | -201.28M | -393.28M | -144.03M |
| Operating CF Margin % | -0.1% | 6.26% | -1.34% | -2.97% | -2.88% | -1.72% | -1.38% | -0.23% |
| Operating CF Growth % | - | 130.5% | -1.27% | -1.68% | 0.11% | -0.01% | -0.95% | 0.63% |
| Net Income | 9.37M | -1.62M | -130.37M | -308.29M | -407.2M | -445.72M | -520.12M | -158.13M |
| Depreciation & Amortization | 217K | 1.68M | 5.26M | 9.93M | 13.92M | 18.39M | 20.45M | 23.36M |
| Stock-Based Compensation | 0 | 704K | 1.27M | 4.76M | 20.16M | 34.34M | 47.68M | 68.94M |
| Deferred Taxes | 0 | -5.66M | -7.35M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 228.87M | -6.13M | -4.36M | 93.83M | 12.82M | 10.68M | 130.06M | -98.24M |
| Working Capital Changes | -16.5M | 318.71M | 52.48M | -23.24M | 161.83M | 181.03M | -71.34M | 20.04M |
| Change in Receivables | -228.06M | 207.61M | -3.77M | -45M | 24.59M | 50.32M | -98.98M | 93.75M |
| Change in Inventory | -6K | -1.12M | -22K | -643K | 51K | -13.89M | -12.71M | -17.21M |
| Change in Payables | 4.17M | 3.24M | 2.01M | -4.35M | 1.8M | 72.45M | -50.2M | 14.06M |
| Cash from Investing | -827K | -102.26M | -58.65M | -24.17M | -194.98M | -77.09M | 92.79M | -850.54M |
| Capital Expenditures | -887K | -21.02M | -39.17M | -26.25M | -42.2M | -20.93M | -20.08M | -14.11M |
| CapEx % of Revenue | 0.04% | 0.43% | 0.63% | 0.35% | 0.61% | 0.18% | 0.07% | 0.02% |
| Acquisitions | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 55K | -75.23M | 50.52M | -23.52M | -4.91M | -16.05M | -100.52M | -54.34M |
| Cash from Financing | 3.32M | 2.5M | 14.67M | 618.88M | 626.66M | 377.98M | 791.49M | 5.7M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - |
| Other Financing | 3.35M | 2.72M | 19.72M | -1.05M | 4.64M | 2.93M | 211.56M | 9.72M |
| Net Change in Cash | - | - | - | - | - | - | - | - |
| Free Cash Flow | -3.26M | 286.66M | -122.23M | -253.29M | -243.87M | -223.56M | -416M | -158.14M |
| FCF Margin % | -0.14% | 5.83% | -1.98% | -3.38% | -3.54% | -1.91% | -1.46% | -0.25% |
| FCF Growth % | - | 88.85% | -1.43% | -1.07% | 0.04% | 0.08% | -0.86% | 0.62% |
| FCF per Share | -0.05 | 5.72 | -1.85 | -4.29 | -3.46 | -2.81 | -4.73 | -1.73 |
| FCF Conversion (FCF/Net Income) | -0.25x | -110.52x | 0.82x | 0.84x | 0.49x | 0.45x | 0.76x | 0.81x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 76.98% | -26.75% | - | -112.18% | -59.19% | -59.11% | -51.94% | -15.45% |
| Return on Invested Capital (ROIC) | 100.15% | - | - | - | -170.38% | -154.35% | -120.93% | -32.33% |
| Gross Margin | 100.41% | 100% | 100% | 100% | 100% | 44.14% | 49.42% | 62.6% |
| Net Margin | 39.69% | -5.67% | -164.39% | -355.16% | -586.38% | -381.48% | -181.75% | -28.22% |
| Debt / Equity | 0.02x | 0.50x | - | 0.01x | 0.16x | 0.38x | 0.26x | 0.34x |
| Interest Coverage | - | -18.71x | -594.23x | - | -435.87x | -42.20x | -20.17x | -14.03x |
| FCF Conversion | -0.25x | -110.52x | 0.82x | 0.84x | 0.49x | 0.45x | 0.76x | 0.81x |
| Revenue Growth | - | 108.24% | 25.78% | 21.36% | -8.23% | 70% | 143.7% | 119.97% |
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Licensing Of Intellectual Property | 5.63M | 4.91M | - | - | - |
| Licensing Of Intellectual Property Growth | - | -12.80% | - | - | - |
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| UNITED STATES | - | 86.37M | - | 234.73M | 434.71M |
| UNITED STATES Growth | - | - | - | - | 85.19% |
| Europe | - | - | - | 15.07M | 47.87M |
| Europe Growth | - | - | - | - | 217.66% |
| CHINA | - | 3.42M | 328K | 179K | 320K |
| CHINA Growth | - | - | -90.42% | -45.43% | 78.77% |
| North America | 75.68M | - | - | - | - |
| North America Growth | - | - | - | - | - |
Legend Biotech Corporation (LEGN) reported $909.0M in revenue for fiscal year 2024. This represents a 3753% increase from $23.6M in 2017.
Legend Biotech Corporation (LEGN) grew revenue by 120.0% over the past year. This is strong growth.
Legend Biotech Corporation (LEGN) reported a net loss of $239.7M for fiscal year 2024.
Legend Biotech Corporation (LEGN) has a return on equity (ROE) of -15.4%. Negative ROE indicates the company is unprofitable.
Legend Biotech Corporation (LEGN) had negative free cash flow of $188.7M in fiscal year 2024, likely due to heavy capital investments.